T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Name: T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Published: 2018
License: Public Domain

National Cancer Institute (NCI) · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

brain-cancer breast-cancer

breast cancer, brain metastasis, brain cancer, ado-trastuzumab emtansine, systemic control of disease, maximum tolerated dose, preventing the formation of a metastasis, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Related documents